Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial

F. H. van der Baan; M. J. Knol; A. H. Maitland-van der Zee; J. J. Regieli; E. P. A. van Iperen; A. C. G. Egberts; O. H. Klungel; D. E. Grobbee; J. W. Jukema

doi:https://doi.org/10.1038/tpj.2012.12

Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial

F. H. van der Baan, M. J. Knol, A. H. Maitland-van der Zee, J. J. Regieli, E. P. A. van Iperen, A. C. G. Egberts, O. H. Klungel, D. E. Grobbee, J. W. Jukema

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

It was investigated whether pharmacogenetic factors, both as single polymorphism and as gene-gene interactions, have an added value over non-genetic factors in predicting statin response. Five common polymorphisms were selected in apolipoprotein E, angiotensin-converting enzyme, hepatic lipase and toll-like receptor 4. Linear regression models were built and compared on R(2) to estimate the added value of single polymorphisms and gene-gene interactions. The selected polymorphisms and the gene-gene interactions had a small added value in predicting change in low-density lipoprotein cholesterol levels (LDL-c) as response to statins over the non-genetic predictors (P=0.104), and also in predicting LDL-c in non-treated patients (P=0.016). Moreover, four gene-gene interactions with statin therapy were identified. The added value of genetic factors over non-genetic variables is for the greater part produced by gene-gene interactions. This underlines the importance to examine gene-gene interactions in future (pharmaco)genetic research

Original language	English
Pages (from-to)	318-324
Journal	pharmacogenomics journal
Volume	13
Issue number	4
DOIs	https://doi.org/10.1038/tpj.2012.12
Publication status	Published - 2013

Access to Document

https://doi.org/10.1038/tpj.2012.12

Cite this

@article{76a5d10bbfcb488d8796aa23241a8454,

title = "Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial",

abstract = "It was investigated whether pharmacogenetic factors, both as single polymorphism and as gene-gene interactions, have an added value over non-genetic factors in predicting statin response. Five common polymorphisms were selected in apolipoprotein E, angiotensin-converting enzyme, hepatic lipase and toll-like receptor 4. Linear regression models were built and compared on R(2) to estimate the added value of single polymorphisms and gene-gene interactions. The selected polymorphisms and the gene-gene interactions had a small added value in predicting change in low-density lipoprotein cholesterol levels (LDL-c) as response to statins over the non-genetic predictors (P=0.104), and also in predicting LDL-c in non-treated patients (P=0.016). Moreover, four gene-gene interactions with statin therapy were identified. The added value of genetic factors over non-genetic variables is for the greater part produced by gene-gene interactions. This underlines the importance to examine gene-gene interactions in future (pharmaco)genetic research",

author = "{van der Baan}, {F. H.} and Knol, {M. J.} and {Maitland-van der Zee}, {A. H.} and Regieli, {J. J.} and {van Iperen}, {E. P. A.} and Egberts, {A. C. G.} and Klungel, {O. H.} and Grobbee, {D. E.} and Jukema, {J. W.}",

year = "2013",

doi = "https://doi.org/10.1038/tpj.2012.12",

language = "English",

volume = "13",

pages = "318--324",

journal = "pharmacogenomics journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial

AU - van der Baan, F. H.

AU - Knol, M. J.

AU - Maitland-van der Zee, A. H.

AU - Regieli, J. J.

AU - van Iperen, E. P. A.

AU - Egberts, A. C. G.

AU - Klungel, O. H.

AU - Grobbee, D. E.

AU - Jukema, J. W.

PY - 2013

Y1 - 2013

N2 - It was investigated whether pharmacogenetic factors, both as single polymorphism and as gene-gene interactions, have an added value over non-genetic factors in predicting statin response. Five common polymorphisms were selected in apolipoprotein E, angiotensin-converting enzyme, hepatic lipase and toll-like receptor 4. Linear regression models were built and compared on R(2) to estimate the added value of single polymorphisms and gene-gene interactions. The selected polymorphisms and the gene-gene interactions had a small added value in predicting change in low-density lipoprotein cholesterol levels (LDL-c) as response to statins over the non-genetic predictors (P=0.104), and also in predicting LDL-c in non-treated patients (P=0.016). Moreover, four gene-gene interactions with statin therapy were identified. The added value of genetic factors over non-genetic variables is for the greater part produced by gene-gene interactions. This underlines the importance to examine gene-gene interactions in future (pharmaco)genetic research

AB - It was investigated whether pharmacogenetic factors, both as single polymorphism and as gene-gene interactions, have an added value over non-genetic factors in predicting statin response. Five common polymorphisms were selected in apolipoprotein E, angiotensin-converting enzyme, hepatic lipase and toll-like receptor 4. Linear regression models were built and compared on R(2) to estimate the added value of single polymorphisms and gene-gene interactions. The selected polymorphisms and the gene-gene interactions had a small added value in predicting change in low-density lipoprotein cholesterol levels (LDL-c) as response to statins over the non-genetic predictors (P=0.104), and also in predicting LDL-c in non-treated patients (P=0.016). Moreover, four gene-gene interactions with statin therapy were identified. The added value of genetic factors over non-genetic variables is for the greater part produced by gene-gene interactions. This underlines the importance to examine gene-gene interactions in future (pharmaco)genetic research

U2 - https://doi.org/10.1038/tpj.2012.12

DO - https://doi.org/10.1038/tpj.2012.12

M3 - Article

C2 - 22547143

SN - 1470-269X

VL - 13

SP - 318

EP - 324

JO - pharmacogenomics journal

JF - pharmacogenomics journal

IS - 4

ER -